Neuroimaging markers of cellular function in major depressive disorder: Implications for therapeutics, personalized medicine, and prevention

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 2, 2012, Pages 201-214

  Meyer, J H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,5,6,10B HEXAHYDRO 6 (4 METHYLTHIOPHENYL)PYRROLO[2,1 A]ISOQUINOLINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ABP 688; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; CARBON 11; CITALOPRAM; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; FLUOXETINE; GLUTAMIC ACID; HARMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; P 943; PAROXETINE; PLACEBO; RADIOPHARMACEUTICAL AGENT; RESERPINE; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 2A AGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANS 4 FLUORO N 2 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]ETHYL] N (2 PYRIDYL) CYCLOHEXANECARBOXAMIDE; UNCLASSIFIED DRUG; VENLAFAXINE;

ANTERIOR CINGULATE; ANXIETY DISORDER; ARTICLE; BRAIN REGION; DIFFUSION WEIGHTED IMAGING; HIPPOCAMPUS; HUMAN; MAJOR DEPRESSION; MEMORY DISORDER; MOTOR RETARDATION; NEUROIMAGING; NONHUMAN; PERSONALIZED MEDICINE; PESSIMISM; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROTEIN BINDING; PUERPERIUM; VERBAL MEMORY;

BRAIN; DEPRESSIVE DISORDER, MAJOR; DRUG DISCOVERY; GLUTAMIC ACID; HUMANS; INDIVIDUALIZED MEDICINE; MODELS, NEUROLOGICAL; MONOAMINE OXIDASE; NEUROIMAGING; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS;

EID: 84855976390     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.285     Document Type: Article

References (75)

1. Patten, S.B. Accumulation of major depressive episodes over time in a prospective study indicates that retrospectively assessed lifetime prevalence estimates are too low. BMC Psychiatry 9, 19 (2009).
2. Frank, E. et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch. Gen. Psychiatry 47, 1093-1099 (1990).
3. Trivedi, M.H. et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163, 28-40 (2006). (Pubitemid 43050100)
4. Youdim, M.B., Edmondson, D. & Tipton, K.F. The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci. 7, 295-309 (2006).
5. Saura, J., Kettler, R., Da Prada, M. & Richards, J.G. Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J. Neurosci. 12, 1977-1999 (1992).
6. Meyer, J.H. et al. Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch. Gen. Psychiatry 63, 1209-1216 (2006). (Pubitemid 44708079)
7. Barton, D.A. et al. Elevated brain serotonin turnover in patients with depression: effect of genotype and therapy. Arch. Gen. Psychiatry 65, 38-46 (2008).
8. Meyer, J.H. et al. Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. Arch. Gen. Psychiatry 66, 1304-1312 (2009).
9. Johnson, S.et al. The reduction of R1, a novel repressor protein for monoamine oxidase A, in major depressive disorder. Neuropsychopharmacology 36, 2139-2148 (2011).
10. Donnelly, C.H. & Murphy, D.L. Substrate-and inhibitor-related characteristics of human platelet monoamine oxidase. Biochem. Pharmacol. 26, 853-858 (1977). (Pubitemid 8074163)
11. Meyer, J.H. et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am. J. Psychiatry 158, 1843-1849 (2001). (Pubitemid 33054777)
12. Meyer, J.H. et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am. J. Psychiatry 161, 826-835 (2004). (Pubitemid 38625335)
13. Meyer, J.H. et al. The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. Am. J. Psychiatry 158, 78-85 (2001). (Pubitemid 32047250)
14. Meyer, J.H. Applying neuroimaging ligands to study major depressive disorder. Semin. Nucl. Med. 38, 287-304 (2008). (Pubitemid 351726327)
15. Meyer, J.H. et al. Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. Am. J. Psychiatry 160, 90-99 (2003). (Pubitemid 36042431)
16. Liotti, M., Mayberg, H.S., McGinnis, S., Brannan, S.L. & Jerabek, P. Unmasking disease-specific cerebral blood flow abnormalities: mood challenge in patients with remitted unipolar depression. Am. J. Psychiatry 159, 1830-1840 (2002). (Pubitemid 35283247)
17. Sharot, T., Riccardi, A.M., Raio, C.M. & Phelps, E.A. Neural mechanisms mediating optimism bias. Nature 450, 102-105 (2007). (Pubitemid 350070573)
18. Tom, S.M., Fox, C.R., Trepel, C. & Poldrack, R.A. The neural basis of loss aversion in decision-making under risk. Science 315, 515-518 (2007). (Pubitemid 46175755)
19. O'Hara, M.W. & Swain, A. Rates and risk of postpartum depression-a meta analysis. Int. Rev. Psychiatry 8, 37-54 (1996).
20. Sacher, J. et al. Elevated brain monoamine oxidase A binding in the early postpartum period. Arch. Gen. Psychiatry 67, 468-474 (2010).
21. O'Hara, M.W., Schlechte, J.A., Lewis, D.A. & Wright, E.J. Prospective study of postpartum blues. Biologic and psychosocial factors. Arch. Gen. Psychiatry 48, 801-806 (1991).
22. Ruh H.G., Mason, N.S. & Schene, A.H. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol. Psychiatry 12, 331-359 (2007). (Pubitemid 46496835)
23. Zarate, C.A. Jr et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63, 856-864 (2006). (Pubitemid 44188478)
24. Kapur, S. & Seeman, P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2) receptorsimplications for models of schizophrenia. Mol. Psychiatry 7, 837-844 (2002).
25. Rajkowska, G. & Miguel-Hidalgo, J.J. Gliogenesis and glial pathology in depression. CNS Neurol. Disord. Drug Targets 6, 219-233 (2007). (Pubitemid 46916253)
26. Hasler, G., van der Veen, J.W., Tumonis, T., Meyers, N., Shen, J. & Drevets, W.C. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry 64, 193-200 (2007). (Pubitemid 46220776)
27. Sanacora, G. et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch. Gen. Psychiatry 61, 705-713 (2004). (Pubitemid 38890805)
28. Deschwanden, A. et al. Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study. Am. J. Psychiatry 168, 727-734 (2011).
29. Stockmeier, C.A. Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter. J. Psychiatr. Res. 37, 357-373 (2003). (Pubitemid 36808810)
30. Barraclough, B., Bunch, J., Nelson, B. & Sainsbury, P. A hundred cases of suicide: clinical aspects. Br. J. Psychiatry 125, 355-373 (1974).
31. McMahon, F.J. et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am. J. Hum. Genet. 78, 804-814 (2006).
32. Yatham, L.N. et al. Brain serotonin2 receptors in major depression: a positron emission tomography study. Arch. Gen. Psychiatry 57, 850-858 (2000).
33. Meyer, J.et al. Prefrontal cortex 5-HT2 receptors in depression: a [18F] setoperone PET imaging study. Am. J. Psychiatry 156, 1029-1034 (1999). (Pubitemid 29302795)
34. Meltzer, C.C. et al. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. Am. J. Psychiatry 156, 1871-1878 (1999).
35. Bhagwagar, Z., Hinz, R., Taylor, M., Fancy, S., Cowen, P. & Grasby, P. Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C]MDL 100,907. Am. J. Psychiatry 163, 1580-1587 (2006). (Pubitemid 44465759)
36. Norman, W.H., Miller, I.W. & Dow, M.G. Characteristics of depressed patients with elevated levels of dysfunctional cognitions. Cog. Ther. Res. 12, 39-51 (1998).
37. Beck, A.T., Steer, R.A., Kovacs, M. & Garrison, B. Hopelessness and eventual suicide: a 10-year prospective study of patients hospitalized with suicidal ideation. Am. J. Psychiatry 142, 559-563 (1985). (Pubitemid 15034623)
38. Frokjaer, V.G. et al. Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder. Biol. Psychiatry 63, 569-576 (2008). (Pubitemid 351273195)
39. Cho, R., Kapur, S., Du, L. & Hrdina, P. Relationship between central and peripheral serotonin 5-HT2A receptors: a positron emission tomography study in healthy individuals. Neurosci. Lett. 261, 139-142 (1999). (Pubitemid 29104964)
40. Mathews, T.A., Fedele, D.E., Coppelli, F.M., Avila, A.M., Murphy, D.L. & Andrews, A.M. Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression. J. Neurosci. Methods 140, 169-181 (2004). (Pubitemid 39625865)
41. Meyer, J.H. et al. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch. Gen. Psychiatry 61, 1271-1279 (2004). (Pubitemid 39602843)
42. Cannon, D.M. et al. Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol. Psychiatry 62, 870-877 (2007). (Pubitemid 47488222)
43. Bhagwagar, Z. et al. 5-HTT binding in recovered depressed patients and healthy volunteers: a positron emission tomography study with [11C]DASB. Am. J. Psychiatry 164, 1858-1865 (2007). (Pubitemid 351739239)
44. Magnusson, A. An overview of epidemiological studies on seasonal affective disorder. Acta Psychiatr. Scand. 101, 176-184 (2000). (Pubitemid 30108368)
45. Praschak-Rieder, N., Willeit, M., Wilson, A.A., Houle, S. & Meyer, J.H. Seasonal variation in human brain serotonin transporter binding. Arch. Gen. Psychiatry 65, 1072-1078 (2008).
46. Kalbitzer, J. et al. Seasonal changes in brain serotonin transporter binding in short serotonin transporter linked polymorphic region-allele carriers but not in long-allele homozygotes. Biol. Psychiatry 67, 1033-1039 (2010).
47. Ruh H.G., Booij, J., Reitsma, J.B. & Schene, A.H. Serotonin transporter binding with [123I]beta-CIT SPECT in major depressive disorder versus controls: effect of season and gender. Eur. J. Nucl. Med. Mol. Imaging 36, 841-849 (2009).
48. Buchert, R. et al. Is correction for age necessary in SPECT or PET of the central serotonin transporter in young, healthy adults? J. Nucl. Med. 47, 38-42 (2006). (Pubitemid 46768510)
49. Willeit, M. & Praschak-Rieder, N. Imaging the effects of genetic polymorphisms on radioligand binding in the living human brain: A review on genetic neuroreceptor imaging of monoaminergic systems in psychiatry. Neuroimage 53, 878-892 (2010).
50. Praschak-Rieder, N. et al. Novel 5-HTTLPR allele associates with higher serotonin transporter binding in putamen: a [(11)C] DASB positron emission tomography study. Biol. Psychiatry 62, 327-331 (2007). (Pubitemid 47444277)
51. Drevets, W.C. et al. PET imaging of serotonin 1A receptor binding in depression. Biol. Psychiatry 46, 1375-1387 (1999).
52. Sargent, P.A. et al. Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch. Gen. Psychiatry 57, 174-180 (2000). (Pubitemid 30075269)
53. Bhagwagar, Z., Rabiner, E.A., Sargent, P.A., Grasby, P.M. & Cowen, P.J. Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Mol. Psychiatry 9, 386-392 (2004). (Pubitemid 38534699)
54. Parsey, R.V. et al. Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY 100635 positron emission tomography study. Biol. Psychiatry 59, 106-113 (2006). (Pubitemid 43117499)
55. Neumeister, A. et al. Reduced serotonin type 1A receptor binding in panic disorder. J. Neurosci. 24, 589-591 (2004). (Pubitemid 38166482)
56. Nash, J.R. et al. Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study. Br. J. Psychiatry 193, 229-234 (2008).
57. Lanzenberger, R.R. et al. Reduced serotonin-1A receptor binding in social anxiety disorder. Biol. Psychiatry 61, 1081-1089 (2007). (Pubitemid 46551966)
58. Stockmeier, C.A. et al. Antagonist but not agonist labeling of serotonin-1A receptors is decreased in major depressive disorder. J. Psychiatr. Res. 43, 887-894 (2009).
59. Murrough, J.W. et al. Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder. Psychopharmacology (Berl.) 213, 547-553 (2011).
60. Meyer, J.H. et al. Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study. Am. J. Psychiatry 163, 1594-1602 (2006). (Pubitemid 44465761)
61. Cannon, D.M., Klaver, J.M., Peck, S.A., Rallis-Voak, D., Erickson, K. & Drevets, W.C. Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [11C]NNC-112. Neuropsychopharmacology 34, 1277-1287 (2009).
62. Dougherty, D.D. et al. Decreased striatal D1 binding as measured using PET and [11C]SCH 23,390 in patients with major depression with anger attacks. Depress. Anxiety 23, 175-177 (2006). (Pubitemid 43727148)
63. Neumeister, A. et al. Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls. Psychol. Med. 31, 1467-1473 (2001). (Pubitemid 33040370)
64. Meyer, J.H. et al. Lower dopamine transporter binding potential in striatum during depression. Neuroreport 12, 4121-4125 (2001). (Pubitemid 33152464)
65. Sarchiapone, M. et al. Dopamine transporter binding in depressed patients with anhedonia. Psychiatry Res. 147, 243-248 (2006). (Pubitemid 44397469)
66. Brunswick, D.J., Amsterdam, J.D., Mozley, P.D. & Newberg, A. Greater availability of brain dopamine transporters in major depression shown by [99m Tc]TRODAT-1 SPECT imaging. Am. J. Psychiatry 160, 1836-1841 (2003). (Pubitemid 41103319)
67. Kilbourn, M.R., Sherman, P.S. & Pisani, T. Repeated reserpine administration reduces in vivo [18F]GBR 13119 binding to the dopamine uptake site. Eur. J. Pharmacol. 216, 109-112 (1992).
68. MacQueen, G.M. et al. Course of illness, hippocampal function, and hippocampal volume in major depression. Proc. Natl. Acad. Sci. USA 100, 1387-1392 (2003). (Pubitemid 36184011)
69. MacQueen, G. & Frodl, T. The hippocampus in major depression: evidence for the convergence of the bench and bedside in psychiatric research? Mol. Psychiatry 16, 252-264 (2011).
70. Sapolsky, R.M. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch. Gen. Psychiatry 57, 925-935 (2000).
71. Sheline, Y.I., Wang, P.W., Gado, M.H., Csernansky, J.G. & Vannier, M.W. Hippocampal atrophy in recurrent major depression. Proc. Natl. Acad. Sci. USA 93, 3908-3913 (1996). (Pubitemid 26144221)
72. Stockmeier, C.A. et al. Cellular changes in the postmortem hippocampus in major depression. Biol. Psychiatry 56, 640-650 (2004). (Pubitemid 39446845)
73. Neumeister, A. et al. Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects. Biol. Psychiatry 57, 935-937 (2005). (Pubitemid 40488364)
74. Frodl, T. et al. Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression. Arch. Gen. Psychiatry 64, 410-416 (2007). (Pubitemid 46556460)
75. Hallahan, B. et al. Structural magnetic resonance imaging in bipolar disorder: an international collaborative mega-analysis of individual adult patient data. Biol. Psychiatry 69, 326-335 (2011).